foxo4-dri peptide senolytic human trial FOXO4-DRI: Status, Cancer Research & Data Frontiers | Senolytic Peptide FOXO4-DRI

Studies show that intravenous administration of 6 ml per ewe of this combination for three consecutive days before parturition has prophylactic effects on metabolic disorders of ewes and enhances the lamb's weight gain after birth

A counteracting agent may be the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, an anti-ulcer peptide per-orally active (12-15) that may also affect many central disturbances (16-23), efficient in inflammatory bowel disease trials (PL 14736) (24, 25) and various wound treatment (26-28), no toxicity reported (12, 13, 24, 25)) which showed various hepatoprotective effects (29-31)

Long-Term: Sustained anti-inflammatory effects, improved joint comfort, and ongoing protection of muscles, connective tissue, and digestive health with continued therapy.

Injury recovery Explored in preclinical research on recovery from acute injury and overuse strain